Frontiers in Allergy (Feb 2025)
EUFOREA meeting on defining disease states in allergic rhinitis: towards a unified language in AR
- G. K. Scadding,
- D. M. Conti,
- D. M. Conti,
- S. Scheire,
- V. Backer,
- M. Blaiss,
- L. O. Cardell,
- L. O. Cardell,
- W. De Yun,
- A. K. Ellis,
- W. Fokkens,
- A. T. Fox,
- T. Gilbert Kruz,
- S. Halken,
- P. W. Hellings,
- P. W. Hellings,
- P. W. Hellings,
- V. Hox,
- L. Kalogjera,
- S. Lau,
- S. Marinho,
- M. McDonald,
- R. Mösges,
- R. Mösges,
- J. Mullol,
- S. Nasser,
- R. Pawankar,
- D. Price,
- D. Price,
- D. Ryan,
- G. Scadding,
- P. Smith,
- M. Sosa Kostrábová,
- M. Vazquez-Ortiz,
- U. Wahn,
- L. Zhang,
- P. Gevaert
Affiliations
- G. K. Scadding
- Royal National ENT Hospital and University College, London, United Kingdom
- D. M. Conti
- Escuela de Doctorado UAM, Centro de Estudios de Posgrado, Universidad Autónoma de Madrid, Calle Francisco Tomás y Valiente, no. 2, Ciudad Universitaria de Cantoblanco, Madrid, Spain
- D. M. Conti
- Allergy and Clinical Immunology Research Unit, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium
- S. Scheire
- Upper Airways Research Laboratory, Department of Head and Skin, Ghent University, Ghent, Belgium
- V. Backer
- Department of Otorhinolaryngology, Head & Neck Surgery, and Audiology, Rigshospitalet, Copenhagen University, Copenhagen, Denmark
- M. Blaiss
- Medical College of Georgia at Augusta University, Augusta, GA, United States
- L. O. Cardell
- Division of ENT Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
- L. O. Cardell
- Department of ENT Diseases, Karolinska University Hospital, Stockholm, Sweden
- W. De Yun
- Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
- A. K. Ellis
- 0Division of Allergy & Immunology, Department of Medicine, Queen’s University, Kingston, ON, Canada
- W. Fokkens
- 1Department of Otorhinolaryngology, Amsterdam University Medical Centres, Amsterdam, Netherlands
- A. T. Fox
- 2Guy’s & St Thomas’ Hospitals NHS Foundation Trust, London, United Kingdom
- T. Gilbert Kruz
- 3Patient Advisory Board, European Forum for Research and Education in Allergy and Airway Diseases, Brussels, Belgium
- S. Halken
- 4Hans Christian Andersen Children’s Hospital, Odense University Hospital, Odense, Denmark
- P. W. Hellings
- Escuela de Doctorado UAM, Centro de Estudios de Posgrado, Universidad Autónoma de Madrid, Calle Francisco Tomás y Valiente, no. 2, Ciudad Universitaria de Cantoblanco, Madrid, Spain
- P. W. Hellings
- 5Laboratory of Upper Airways Research, Department of Otorhinolaryngology, University of Ghent, Ghent, Belgium
- P. W. Hellings
- 6Clinical Department of Otorhinolaryngology, Head and Neck Surgery, University Hospitals Leuven, Leuven, Belgium
- V. Hox
- 7Department of Otorhinolaryngology, Cliniques Universitaires Saint Luc, Brussels, Belgium
- L. Kalogjera
- 8Department of Otorhinolaryngology/Head and Neck Surgery, University Hospital Centre “Sestre milosrdnice”, Zagreb School of Medicine, Zagreb, Croatia
- S. Lau
- 9Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany
- S. Marinho
- 0Allergy Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust and The University of Manchester, Manchester, United Kingdom
- M. McDonald
- 1The Allergy Clinic, Johannesburg, South Africa
- R. Mösges
- 2ClinCompetence Cologne GmbH, Cologne, Germany
- R. Mösges
- 3Institute of Medical Statistics and Computational Biology, Faculty of Medicine, University of Cologne, Cologne, Germany
- J. Mullol
- 4Rhinology Unit & Smell Clínic, Department of Otorhinolaryngology, Hospital Clínic Barcelona, Universitat de Barcelona; FRCB-IDIBAPS; CIBERES, Barcelona, Catalonia, Spain
- S. Nasser
- 5Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
- R. Pawankar
- 6Department of Pediatrics, Nippon Medical School, Bunkyo-ku, Tokyo, Japan
- D. Price
- 7Observational and Pragmatic Research Institute, Singapore, Singapore
- D. Price
- 8Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom
- D. Ryan
- 9Usher Institute, University of Edinburgh, Edinburgh, Scotland
- G. Scadding
- 0Allergy Department, Royal Brompton Hospital, London, United Kingdom
- P. Smith
- 1Griffth University, Southport, QLD, Australia
- M. Sosa Kostrábová
- 3Patient Advisory Board, European Forum for Research and Education in Allergy and Airway Diseases, Brussels, Belgium
- M. Vazquez-Ortiz
- 2Section of Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, London, United Kingdom
- U. Wahn
- 3Charite University Medicine, Berlin, Germany
- L. Zhang
- 4Department of Otolaryngology Head and Neck Surgery and Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, China
- P. Gevaert
- Upper Airways Research Laboratory, Department of Head and Skin, Ghent University, Ghent, Belgium
- DOI
- https://doi.org/10.3389/falgy.2024.1531788
- Journal volume & issue
-
Vol. 5
Abstract
Allergic rhinitis (AR), the most prevalent immunological disease, affects approximately 400 million individuals globally and can significantly impact quality of life (QoL). Despite nearly 25 years of guidelines, AR remains largely under- diagnosed, suboptimally treated and poorly controlled. In the light of new knowledge and treatment options, there is a necessity to update or revise fundamental AR definitions to facilitate communication across diverse specialties engaged in its treatment and to improve patient care. The European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) convened a meeting of experts and patient representatives to deliberate the optimal methodology for measuring AR treatment responses and establishing novel treatment goals. This paper presents a consensus on revised AR definitions, including control, severe allergic rhinoconjunctivitis (SARC), refractory severe allergic rhinoconjunctivitis (R-SARC), remission, resolution, improvement, exacerbation, treatable traits (TTs), treat to target, relapse, progression, disease modification, and prevention.
Keywords
- allergic rhinitis
- quality of life
- definitions
- severe allergic rhinoconjunctivitis (SARC)
- refractory severe allergic rhinoconjunctivitis (R-SARC)
- biologics
